newsfilter
← Latest News
GlobeNewswire·

VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demo